COVID-19 Information Center

Novartis is responding to COVID-19 with safety of associates and patients globally our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.

Novartis announces further steps to protect and support associates

As the coronavirus (COVID-19) situation evolves, work from home guidance is extended and we are also supporting associates as they adapt to new working dynamics and family commitments

Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the COVID-19 response

Illustration of the coronavirus created at the Centers for Disease Control and Prevention (CDC)

Coronavirus disease (COVID-19) news

Latest media releases and statements in the Novartis Newsroom

Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities

Novartis coronavirus update March 13, 2020 (remote working, business travel restrictions)

Novartis coronavirus update March 11, 2020 (supply chain, response measures, EFPIA R&D call)

Sandoz commits to keep prices stable for basket of essential medicines amid growing concerns about supply impact of coronavirus

Guidance

Job candidates

Novartis is supporting candidates during the COVID-19 outbreak. During this time interviews will continue as planned and, where appropriate, will be switched to virtual interviews using readily available technology.

Learn More

Research and collaborations

COVID-19 Therapeutics Accelerator

Novartis has joined the accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard

Learn More

Innovative Medicines Initiative (IMI)

Novartis is part of a consortium engaging with the Innovative Medicines Initiative (IMI) on their COVID-19 directed efforts.

About IMI

EFPIA call for therapeutic treatments R&D

Novartis is making available several compounds from our libraries that are considered suitable for in vitro antiviral testing

Learn More

Novartis research into Coronavirus (COVID-19)

Novartis is also rapidly evaluating other existing products to see if any could be utilized beyond their approved indications in response to the pandemic.

Perspectives

Choosing optimism in the face of crisis

LinkedIn article written by Vas Narasimhan, CEO of Novartis

Resources

World Health Organization (WHO)

WHO coronavirus disease (COVID-19) resources

Learn More

CDC's Tom Harkin Global Communications Center

US Centers for Disease Control and Prevention (CDC)

CDC coronavirus disease (COVID-19) resources

Learn More

COVID-19 Tracker

Microsoft’s coronavirus disease outbreak tracker includes data from the WHO, CDC (US) and European CDC.

Latest Tracker